Thymidylate Synthase and Pemetrexed Sensitivity in Lung Cancer
Author Information
Author(s): Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K
Primary Institution: Kinki University Faculty of Medicine
Hypothesis
Does thymidylate synthase (TS) expression affect pemetrexed sensitivity in non-small cell lung cancer (NSCLC)?
Conclusion
A high level of TS expression confers a reduced sensitivity to pemetrexed.
Supporting Evidence
- TS-overexpressing NSCLC cells showed reduced sensitivity to pemetrexed compared to control cells.
- High TS expression in tumors was associated with a poor response to pemetrexed treatment.
- Patients with low TS expression had longer progression-free survival than those with high TS expression.
Takeaway
If a cancer has a lot of a protein called thymidylate synthase, it might not respond well to a drug called pemetrexed.
Methodology
The study involved creating NSCLC cell lines that overexpress TS and testing their sensitivity to pemetrexed in vitro and in vivo.
Potential Biases
Potential biases in patient selection and retrospective analysis.
Limitations
The study's findings may not be generalizable beyond the specific patient population studied.
Participant Demographics
24 patients with advanced NSCLC, including 17 males and 7 females, with a mean age of 66 years.
Statistical Information
P-Value
0.038
Statistical Significance
p=0.038
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website